


# Volpara Scorecard

Women diagnosed during the earliest stages of breast cancer have better outcomes and survival rates.<sup>1</sup> Volpara® Scorecard™ software provides your breast care team with the insights they need to find cancer earlier. Easily accessed from the radiologist’s workstation, Volpara Scorecard streamlines your workflow to improve clinical decision-making and create a better patient experience.



### 3 breast cancer risk insights, 1 customizable view

#### ① Volpara® TruDensity™

Automated, objective, volumetric breast density measurements and a breast density category for an objective and consistent assessment<sup>2</sup>

#### ② Volpara® Risk™\*

Tyrer-Cuzick v8 Risk Evaluation Tool to calculate lifetime risk of developing breast cancer<sup>3</sup>

#### ③ Suspicious findings score\*\*

Machine learning-based analysis to categorize mammograms by the likelihood of the presence of cancerous lesions<sup>4</sup>

\* Available as an integration with Volpara® Patient Hub™ software

\*\* Available as an integration with ScreenPoint Medical (Transpara®) or iCAD software

Automatic density assessment



Lifetime risk



Suspicious findings



Personalized screening approach

#### References

1. Clinical outcomes in very early breast cancer (≤ 1cm): A national population based analysis. Mahvish Muzaffar, Abdul Rafeh Naqash, Nasreen A. Vohra, Darla K. Liles, and Jan H. Wong Journal of Clinical Oncology 2017 35:15\_suppl, e12034-e12034

2. Gubern-Mérida, A., Kallenberg, M., Platel, B., Mann, R.M., Marti, R. and Karssemeijer, N. (2014) Volumetric Breast Density Estimation from Full-Field Digital Mammograms: A Validation Study. PLoS ONE; 9: e85952

3. Terry, M.B. et al. 10-year performance of four models of breast cancer risk: a validation study. Lancet Oncol 20, 504–517 (2019).

4. Rodriguez-Ruiz et al., Can we reduce the workload of mammographic screening by automatic identification of normal exams with artificial intelligence? A feasibility study. Eur Radiology. 2019; 29@: pp 4825–4832

BI-RADS is a registered trademark of the American College of Radiology and American College of Radiology Association. Transpara is a registered trademark of ScreenPoint Medical BV. Copyright © Volpara Health Technologies Ltd. 2021. All rights reserved.

## Clinical decision support for personalized breast care

Volpara Scorecard is available to radiologists during mammography interpretation as a DICOM Secondary Capture Image. This customizable image also includes these features:

- Volpara® TruRadDose™ and Volpara® TruPressure™ clinical functions provide quality control measures for study dose and compression pressure, respectively.
- Integration allows Volpara Risk and suspicious findings score (of either the Transpara Exam Score or iCAD Case Score) to be included in DICOM Mammography CAD Structured Reports.
- Alerts indicate when the patient meets high-risk thresholds.

## Evidence for essential screening

Referring physicians and insurers require evidence of high breast density. Volpara Scorecard's objective, science-based measures help you triage women at high risk to the screening or diagnostic testing essential for better outcomes.

## Effective triage for time and cost savings

Personalized screening scores help the radiologist guide a client with high breast density to essential imaging while they're still in the facility, saving an extra trip and the cost of scheduling an additional appointment.

Combined with Volpara® Analytics™ software, Volpara Scorecard assists in identifying populations with high breast density that may require additional services.

### > FIND OUT MORE

## About Volpara Scorecard

To see how the new Volpara Scorecard can support your breast screening program, contact your Volpara Health representative for a live demonstration, or visit our website.

## About Volpara

Volpara Health is the leading provider of breast imaging analytics and analysis products that improve clinical decision-making and the early detection of breast cancer. Every day, Volpara remains focused on its mission to help save families from cancer.

## Why radiologists choose Volpara's automated breast density assessment:

# 4-6x

**Greater risk** for clients with dense breasts to develop breast cancer when compared to those with fatty breasts

# -30%

**Sensitivity** in mammographic cancer detection for clients with dense breasts when compared to those with fatty breasts

# 89%

Average agreement with the VDG category\*

# 96%

Average agreement with Volpara's assessment of fatty (a/b) or dense (c/d)\*

\*By trained, expert radiologists in clinical practice

# 57%

Inter-reader agreement

# 77%

Intra-reader agreement

Visual density assessment is not always consistent

## Contact

info@volparahealth.com  
support@volparahealth.com

US +1 855 607 0478  
AUS 1800 370 623  
NZ 0800 444 148

Europe +44 203 051 1029  
Global +64 4 499 6029

## Connect

 @VolparaHealth

 @volpara

 Volpara Health